Evaluating treatment outcomes for hormone-sensitive metastatic prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the clinical outcomes of various treatments, including docetaxel and androgen-receptor targeting agents, either alone or in combination with radiotherapy, for patients with hormone-sensitive metastatic prostate cancer. The study will analyze data from an unselected population receiving these treatments in routine clinical practice. It will focus on patients who have recently initiated hormone therapy and will collect clinical data from their medical records to evaluate treatment effectiveness.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. histologically confirmed diagnosis of adenocarcinoma of the prostate, metastatic, not undergoing previous treatment (except hormone therapy initiated no more than 4-6 months prior to docetaxel) for metastatic disease
2. treatment with docetaxel, ARPI (alone or in combination) or with radiation therapy on the primary tumor in combination with ADT within normal clinical practice or expanded access programs initiated between January 2015 and December 2027.
3. availability of inpatient and/or outpatient medical records for clinical data collection

Exclusion Criteria:

1. histological diagnosis other than adenocarcinoma
2. patients who have received multiple lines of ADT for mCSPC
3. patients who have received docetaxel or ARTA for metastatic castration-resistant disease

Where it's running

• Azienda Ospedaliera San Luigi
  Orbassano, Torino, Italy Recruiting
• Istituto Oncologico Veneto
  Padova, Italy Recruiting
• Santa Chiara Hospital
  Trento, Italy Recruiting

Study contacts

• Study coordinator: Orazio Caffo, MD
• Email: orazio.caffo@apss.tn.it
• Phone: +390461904416

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Mevrometostat plus enzalutamide versus enzalutamide alone for men with metastatic castration‑sensitive prostate cancer who are ARPI‑naïve

  This trial will test whether adding the investigational drug mevrometostat to enzalutamide helps men with metastatic castration‑sensitive prostate cancer who have not received androgen receptor pathway inhibitors or chemotherapy.

  Recruiting at 145 sites Phase 3 Pfizer · Huntsville, Alabama and 318 other locations · NCT07028853

• Radiation therapy for recurrent prostate cancer

  This study is testing a new way to use radiation therapy for men with recurrent prostate cancer to see if it helps control the cancer better while also keeping their quality of life intact.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06392295

• Treatment for recurrent prostate cancer with metastases

  This study is testing whether combining hormone therapy with targeted radiation or surgery can help men with recurrent prostate cancer live longer without their cancer spreading.

  Recruiting Phase 3 Universitaire Ziekenhuizen KU Leuven · Leuven · NCT05352178

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.